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ABSTRACT
Objective: This study aimed to develope a simple reversed-phase high performance chromatographic method for simultaneous determination of 
pseudoephdrine  HCI,  pheniramine  maleate,  acetaminophen,  guaifenisin,  pyrilamine  maleate,  chlorpheniramine  maleate,  triprolidine  HCI, 
dextromethorphan HBr, diphenhydramine HCI in cough and cold pharmaceuticals.
Methods: The  separation  of  these  compounds  was  achieved  within  37.9  min  on  a  Nucleodur  gravity  C18  column (250  x  4.0  mm,  5μm).  The 
chromatographic separation of these compounds performed in a single run by using isocratic mobile phase consisting of methanol:buffer mixture
(38:62, v/v) at room temperature, with flow rate of 0.75 mL.min-1.
An  ultraviolet  absorption  at  210  nm  was  monitored.  2,4,6-trimethoxybenzaldehyde  was  used  as  an  internal  standard  (ISTD). The  selectivity, 
linearity of calibration, accuracy, intraday and interday precision and forced degradation studies were examined as parts of the method validation.
Results: The concentration–response relationship was linear over a concentration range of 0.2-250 µg.mL-1 for acetaminophen, 0.5–250 µg.mL-1 for 
pseudoephdrine HCI and pheniramine maleate, 1–250 µg.mL-1 for guaifenisin, 2.5-250 µg.mL-1 for chlorpheniramine maleate and triprolidine HCI, 5- 
250 µg.mL-1 for pyrilamine maleate and diphenhydramine HCI, 10-20 µg.mL-1 for dextromethorphan HBr with correlation coefficients better than 
0.9993. The relative  standard  deviations of  the  intraday  and interday  were  all  less than  4%. Conclusion: The  proposed  liquid chromatographic 
method  was  successfully  applied  for  the  routine  analysis  of  these  compounds  in  different  cough  and  cold  pharmaceutical  preparations  such  as
syrups and tablets.
Keywords: High performance liquid chromatography, Active Ingredients Cough and Cold Pharmaceuticals, Validation. 
 
INTRODUCTION 
Cough and cold pharmaceutical preparations are one of the most 
extended formulations in the world and have got many 
pharmaceutical forms: syrup, suspension, sachets, capsules and 
tablets [1]. These preparations represent complex formulations 
containing several active ingredients and a broad spectrum of 
excipients such as flavoring agents, saccharose or aspartame, 
acidulants, natural or artificial colorings and flavoring agents, dyes 
sweeteners and preservatives [2,3]. These compounds are contained 
in the pharmaceutical form in very different proportions and 
present chemical forms of very different nature [4]. 
Acetaminophen (paracetamol) is analgesic and antipiretic [5]. As 
pain and fever are common, no home should be without some 
paracetamol, particularly homes with children. Acetaminophen is 
available in many different pharmaceutical preparations such as 
tablets, capsules, and liquid suspensions [6]. Chlorpheniramine 
maleate inhibits the effects of histamine on capillary permeability 
and bronchial smooth muscles. It is an anti-allergic drug, widely 
used in cough-cold preparations. The combination of antihistamine 
such as pyrilamine maleate and chlorpheniramine maleate is used to 
overcome the allergic effects and reduce or relieve cold symptoms 
[3]. Pheniramine maleate, dipenhydramine HCI, triprolidine HCI and 
pseudoephedrine hydrochloride are widely used in combination 
with other drugs for the clinical treatment of common cold, sinusitis, 
bronchitis and respiratory allergies [7]. Two common actives in such 
products are dextromethorphan HBr and guaifenesin. 
Dextromethorphan HBr is an antitussive which acts through 
depression of the medullary centers of the brain to decrease the 
involuntary urge to cough [8-11]. Guaifenesin is an expectorant 
believed to stimulate receptors that initiate a reflex secretion of 
respiratory tract fluid, thereby increasing the volume while 
decreasing the viscosity of mucus in the lungs. This action facilitates 
removal of mucus and reduces irritation of the bronchial tissue. 
Dextromethorphan hydrobromide and guaifenisin were used as 
cough suppressants antitussive for the relief of nonproductive cough 
and cold preparations [12]. All these components have different 
polarities and exist in very different proportion. Due to these 
characteristics and because of diverse properties inherent to their 
formulation, these preparations offer an analytical problem [13]. 
A variety of methods exist in the literature for the determination of 
some of these compounds [6,14-23]. Among them Louhaichi et al., 
have provided maximum separation that six active ingredients were 
separated, simultaneously [23]. But the presented study has 
identified the separation of nine active ingredients simultaneously. 
The aim of this study was to develop basic, accurate and selective LC 
method for the simultaneous determination of pseudoephdrine HCI, 
pheniramine maleate, acetaminophen, guaifenisin, pyrilamine 
maleate, chlorpheniramine maleate, triprolidine HCI, 
dextromethorphan HBr, diphenhydramine HCI in cough and cold 
pharmaceuticals. The method was then subjected to validation. The 
validation characteristics were evaluated as the selectivity, intraday 
and interday precision, linearity, accuracy, LOQ and LOD values and 
stress forced degradation studies. 
The proposed liquid chromatographic method was successfully 
applied for the routine analysis of these compounds in different 
cough and cold pharmaceutical preparations such as syrups and 
tablets. 
MATERIALS AND METHODS 
Instrumentation and Chromatographic Conditions 
The integrated high performance liquid chromatography system (LC 
1100, Hewlett-Packard, USA) is equipped with a diode-array UV 
detector, a quarternary pump, a degasser, an autosampler, an 
injector with 20 µL loop, and a column oven. Different columns were 
tested for analysis and pseudoephedrine HCI and acetaminophen 
peaks was observed to overlap in the other columns. Therefore 
separation was carried out using Nucleodur gravity C18 column 
(250 x 4.0 mm, 5μm). 
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The mobile phase was a mixture of 38% methanol, 62% of 80 mM 
KH2PO4 aqueous solution adjusted to pH 3.0, to which was added 
10% (v/v) orthophosphoric acid. The mobile phase was vacuum-
filtered through a 0.45 μm nylon filter and degassed on-line by micro 
vacuum degasser. The chromatographic separation of these 
compounds performed at room temperature. Analysis was run at 
flow rate of 0.75 mL.min-1 with 37.9 min run time. The analysis was 
carried out at 210, 220, 254 and 280 nm and the best separation and 
high peak area have been monitored at 210 nm. The injection 
volume was 20 μL. 
Reagents and Chemicals 
Pheniramine maleate, acetaminophen, guaifenisin, pyrilamine 
maleate, chlorpheniramine maleate, triprolidine HCI, 
dextromethorphan HBr, diphenhydramine HCI, HPLC grade 
methanol, sodium benzoate, 1,2-propylene glycol, citric acid, sorbitol 
and sodium saccharin were purchased from Sigma-Aldrich. Sodium 
carboxymethyl cellulose, pseudoephdrine HCI, 2,4,6-
trimethoxybenzaldehyde, sunset yellow, and orthophosphoric acid 
were purchased from Fluka. Potassium dihydrogenphosphate and 
glycerol were obtained from Riedel-de Haën. Orange and cinnamon 
flavor were purchased from Eurofragance.  
Water was purified (18 MΩ cm−1 quality) from New Human Power I 
(Korea).  
The commercialized pharmaceutical products used are detailed 
below: 
Actidem syrup (10 mg dextromethorphan HBr, 30 mg 
pseudoephedrine HCI and 1.25 mg/5 mL triprolidine HCI for 150 
mL) was manufactured by GlaxoSmithKline, France. 
Actifed syrup (30 mg pseudoephedrine HCI and triprolidine HCI 1.25 
mg/5 mL for 150 mL) was manufactured by GlaxoSmithKline, 
France.  
Aferin plus pediatric syrup (160 mg acetaminophen, 1 mg 
chlorpheniramine maleate, 15 mg/5 mL for 100 mL) was 
manufactured by Hüsnü Arsan, Turkey. 
Benical syrup (10 mg dextromethorphan HBr, 20 mg 
pseudoephedrine HCI, 2 mg/5 mLchlorpheniramine maleate for 100 
mL) was manufactured by Bayer, Germany. 
Corsal syrup (120 mg acetaminophen, 2 mg chlorpheniramine 
maleate, 5 mg/5 mL phenylephrine HCI for 120 mL) was 
manufactured by İ.E Ulagay, Turkey. 
Katarin pediatric syrup (120 mg acetaminophen, 50 mg oxolamine 
citrate, 1 mg/5 mL chlorpheniramine maleate for 100 mL) was 
manufactured by Biofarma, Turkey. 
Kongest syrup (160 mg acetaminophen, 2.5 mg chlorpheniramine 
maleate, 1 mg/5 mL phenylephrine HCI for 100 mL) was 
manufactured by Eczacıbaşı, Turkey. 
Peditus syrup (120 mg acetaminophen, 50 mg guaifenesin, 6.25 mg 
pyrilamine maleate, 5 mg/5 mL phenylephrine HCI for 100 mL) was 
manufactured by Sandoz, Turkey. 
Sudafed syrup (30 mg/5 mL pseudoephedrine HCI for 150 mL) was 
manufactured by GlaxoSmithKline, France. 
Benical cold film tablet (500 mg acetaminophen, 30 mg 
pseudoephedrine HCI, 20 mg dextromethorphan HBr for one tablet) 
was manufactured by Bayer, Germany. 
Corsal capsule (300 mg acetaminophen, 2 mg chlorpheniramine 
maleate, 5 mg phenylephrine HCI for one tablet) was manufactured 
by İ.E Ulagay, Turkey. 
Gerakon fort tablet (650 mg acetaminophen, 10 mg phenylephrine 
HCI, 4 mg chlorpheniramine maleate for one tablet) was 
manufactured by Münir Şahin, Turkey. 
Kongest forte tablet (650 mg acetaminophen, 4 mg chlorpheniramine 
maleate, 10 mg phenylephrine HCI for one tablet) was manufactured 
by Eczacıbaşı, Turkey. 
Sudafed syrup (60 mg pseudoephedrine HCI for one tablet) was 
manufactured by GlaxoSmithKline, France. 
Theraflu forte film tablet (650 mg acetaminophen, 10 mg 
phenylephrine HCI, 4 mg chlorpheniramine maleate for one tablet) 
was manufactured by Novartis, Switzerland. 
All these medicines were purchased by local pharmacy. 
Standard solutions and sample preparation for quantification 
Stock standard solutions of pseudoephdrine HCI, pheniramine 
maleate, acetaminophen, guaifenisin, pyrilamine maleate, 
chlorpheniramine maleate, triprolidine HCI, dextromethorphan HBr 
and diphenhydramine HCI were prepared in ultrapure water. The 
calibration curves were prepared by diluting the stock solution in 
the mobile phase to furnish solutions with final concentrations of 
0.2-250 µg.mL-1 for acetaminophen, 0.5–250 µg.mL-1 for 
pseudoephdrine HCI and pheniramine maleate, 1–250 µg.mL-1 for 
guaifenisin, 2.5-250 µg.mL-1 for chlorpheniramine maleate and 
triprolidine HCI, 5-250 µg.mL-1 for pyrilamine maleate and 
diphenhydramine HCI, 10-250 µg.mL-1 for dextromethorphan HBr. 
The syrup placebo was prepared wherein: Citric acid was dissolved 
in glycerin. Sodium benzoat, sorbitol and sodium saccharin were 
dissolved in ultra pure water. Sodium carboxymethyl cellulose was 
kept in water for swelling. Then propylene glycol, flavors and 
colouring agent were added to this mixture and diluted with 
ultrapure water to 100 mL [24]. The excipients of syrup placebo 
were shown in Table 1.  
Table 1: Excipients of placebo syrup 
Excipients  Amount 
Citric Acid 0.3 g 
Glycerin 10 g 
Propylene glycol 10 g 
Sodium benzoat 0.02 g 
Sodium carboxymethyl cellulose 0.1 g 
Sorbitol 20 g 
Sodium saccharin 0.04 g 
Sunset yellow enough amount 
Orange aroma 1 drop 
Cinnamon aroma 1 drop 
 
The amounts of the commercial cough and cold liquid were 
depending on the drug concentration of various products. The 
commercial cough and cold syrups were diluted with mobile phase 
according to linear range of standards. The resulting solutions were 
vortexed for 15 min and a portion of the sample was filtered through 
a 0.45 µm filter before injection in the HPLC. 
The mean weight of finely powdered tablets were accurately 
transferred into 50 mL calibrated flask and ultrapure water was 
added. The mixtures were extracted in the ultrasonic bath for 15 
min at room temperature and diluted with ultrapure water to the 
mark. The solutions were filtered through a 0.45 µm filter. Then the 
solutions were diluted with mobile phase depending on the drug 
concentration of various products. All preparations were performed 
in three replicates. 
System Suitability Tests 
As system suitability test is an integral part of chromatographic 
methods development and it is used to verify that the system is 
adequate for the analysis to be performed, the parameters for 
pseudoephdrine HCI, pheniramine maleate, acetaminophen, 
guaifenisin, pyrilamine maleate, chlorpheniramine maleate, 
triprolidine HCI, dextromethorphan HBr and diphenhydramine HCI 
were evaluated. Several parameters may be used to demonstrate 
that the chromatographic system as a whole continues to be fit for 
the intended purpose. As well as monitoring the column 
performance, we can monitor the performance of the injector, 
pumps, and detector and so together provide an overview of system 
suitability. The user may define the minimum performance values or 
acceptance criteria according to local needs or business 
requirements [25]. 
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System suitability test parameters were checked to ensure that the 
system was working correctly during the analysis [26]. Parameters 
which are typically used in suitability evaluations are capacity factor 
(k’), selectivity factor (α), resolution (R), number of theoretical plates 
(N) and tailing factor (T). For an optimum separation, capacity factor 
should be in the range of 0.5 < k’ <10. A value of 1.5 for resolution 
implies a complete separation of two compounds. The number of 
theoretical plates must be higher than 2000. The calculated values of 
tailing factor should be in the range of 0.5 ≤ T ≤ 2. 
 Validation 
A full validation of assay consisting of selectivity, linearity, lower 
limit of detection and quantitation (LOD and LOQ), intraday and 
interday accuracy and precision of the method was performed 
according to the ICH description [27]. 
Selectivity 
Selectivity is the ability to assess unequivocally the analyte in the 
presence of components which may be expected to be present.  
Linearity and Range 
The linearity of the assay was performed with a six point calibration 
curve prepared by diluting stock analyte solution in placebo syrup 
sample for five consecutive days. Six point calibration curves of each 
analyte were obtained by linear regression analysis. 
The lowest concentration that can be quantified (LOQ) with 
acceptable accuracy and precision was evaluated at a signal-to-noise 
ratio of 10. Limit of detection (LOD) was evaluated at a signal-to-
noise ratio of 3. 
Accuracy and Precision 
The accuracy of the proposed procedure was evaluated by means of 
recovery experiments. Recoveries were calculated as peak area 
ratios of reference standard/analyte (spiked placebo) at different 
concentration. 
The precision was expressed as relative standard deviation of a 
series of measurements. Three different concentrations of standard 
solutions were analyzed five consecutive days and five times within 
the same day. 
Forced Degradation Conditions  
Forced degradation studies was carried out to demonstrate that the 
method was stability indicating. Solutions were prepared containing 
each substance at working standard concentration. They were 
treated with the following conditions: 
a) Acid conditions: Solutions were acidulated with 37% HCl to reach 
a final concentration of 0.1 M HCl and heated for 2 h and 8 h at 80⁰C, 
respectively.  
b) Basic conditions: Solutions were treated with 1 M NaOH to reach 
a final concentration of 0.1 M NaOH and heated for 2 h and 8 h at 
80⁰C, respectively. 
c) Oxidation with H2O2: Solutions were treated with 3% (v/v) H2O2 
for 2 h and 8 h, respectively. 
d) UV radiation: Solutions were exposed under a UV light at 254 nm 
during 35 h.  
e) Thermal conditions: Solutions were heated for 2 h, 8 h and 24 h at 
60 ⁰C and 80 ⁰C, respectively. 
RESULTS AND DISCUSSION 
Method Optimization 
The first step of the study was the optimization of the 
chromatographic conditions. Various mobile phase combinations 
were tried initially to separate pseudoephdrine HCI, pheniramine 
maleate, acetaminophen, guaifenisin, pyrilamine maleate, 
chlorpheniramine maleate, triprolidine HCI, dextromethorphan HBr 
and diphenhydramine HCI on C18 column. The mixture of methanol 
and phosphate buffer (38:62, v/v) was capable of a good separation 
and sensitivity (Figure1). 
 
Fig. 1: Effect of methanol and phosphate buffer composition on 
separation of the mixture 
The effect of phosphate buffer concentration (20, 40, 60, 80 ve 100 
mM ) on the retention time of mixture was investigated in methanol-
buffer (38:62) mobile phase. The concentration of the phosphate 
buffer solution was chosen as 80 mM for optimum separation 
(Figure 2). 
 
Fig. 2: Effect of phosphate buffer concentration on separation of 
the mixture. 
In order to find suitable buffer pH, the effect of pH on retention and 
resolution was investigated over the range of 2.0 and 6.0, using 10% 
(v/v) ortho-phosphoric acid solution. pKa values of these compounds 
are higher than 8. The changes in retention time as a function of pH 
result from changes in the ionization form of these solutes. 
Therefore, a pH value of 3.0 was selected because of optimum 
resolution. As shown in Figure 3, the resolution of all active 
compounds under the optimum conditions was adequate. 
 
Fig. 3: Effect of phosphate buffer pH on separation of the mixture 
 
Fig. 4: A typical chromatogram of standard active ingredients. 1, 
maleic acid; 2, acetaminophen; 3, pseudoephedrine HCI; 4, 
pheniramine maleate; 5, guaifenisin; 6, pyrilamine maleate; 7, 
2,4,6-trimethoxybenzaldehyde; 8, chlorpheniramine maleate; 9, 
triprolidine HCI; 10, dextromethorphan HBr; 11, 
diphenhydramine HCI. 
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The important parameter t0 was 2.319± 0.062 min in the 
analysis. This was the time of KBr peak. The capacity factor (k') 
values were in the range of 0.5 < k’ <10 except 
dextromethorphan HBr and diphenhydramine HCI. The 
resolution value for separation of acetaminophen and 
pseudoephedrine HCI was 1.3801 and dextromethorphan HBr 
and diphenhydramine HCI was 1.4995. The resolution values of 
other compounds were higher than 1.5. The therotical plate 
numbers of all compounds were higher than 2600 and the 
calculated tailing factors of them were obtained in the acceptable 
range of 0.5 ≤ T ≤ 2.  
Selectivity 
 The representive chromatogram (Figure 5) of placebo solution 
constituted by excipient blend showed that there was no interfering 
peak in the retention times corresponding to the analytes. Therefore, 
the proposed method was considered to be selective. 
 
 
Fig. 5: Chromatogram of placebo solution, 1. citric acid; 2. sodium benzoate. 
 
Linearity and Range 
To evaluate linearity of the method, six different concentrations of 
the nine analytes in the range of 0.2-250 mg mL-1 for acetaminophen, 
0.5-250 mg mL-1 for pseudoephedrine HCI and pheniramine maleate, 
1-250 mg mL-1 for guaifenisin, 5-250 mg mL-1 for pyrilamine maleate 
and diphenhydramine HCI, 2.5-250 mg mL-1 for chlorpheniramine 
maleate and triprolidine HCI, 10-250 mg mL-1for dextromethorphan 
HBr were analysed and the calibration curves for nine active 
compounds constructed under optimum conditions as the ratio of 
the peak areas of analysed subtance to internal standard against the 
concentration and the results are presented in Table 2. 
The limit of detection (LOD) and limit of quantification (LOQ) of the 
method were determined by injecting progressively low 
concentrations of the standard solutions. 
Accuracy and Precision 
Accuracy was evaluated with recoveries obtained in the analysis of 
synthetic sample prepared in the placebo and compared with the 
corresponding standards. The results indicate good accuracy of the 
method for the simultaneous determination of the active compounds 
as revealed by mean recovery data. The results are given in Table 3. 
For evaluation of the precision estimates, intra-day and inter-day 
precision were performed for each active compound. The intra-day 
precision of the method was determined by preparing the standards 
of nine active compounds at three different concentration and values 
for each compounds were determined by five repeated analyses. 
Inter-day precision was check with the same concentration as intra-
day assay, and the determination of each active compound was 
repeated day by day during five days. The obtained results are 
shown in Table 3.  
 









































0.0222 0.0047 0.0188 0.0175 0.0011 0.0092 0.0162 0.0046 0.0243 
Standard 
error of  
slope 








0.2-250 0.5-250 0.5-250 1-250 5-250 2.5-250 2.5-250 10-250 5-250 
LOD  
(mg L-1) 
0.1 0.1 0.2 0.2 0.2 0.5 0.75 2.5 0.75 
LOQ  
(mg L-1) 
0.3 0.5 0.75 1 5 2.5 2.5 10 5 
 
Forced Degradation 
The drug substances was found almost stable in peroxide 
degradation. No degradation was seen in 3% H2O2 at 80 °C up to 2 
and 8 hours.  
Under the acidic conditional at the end of 2h and 8 h, large amount of fall 
in active compounds peaks area was observed except guaifenisin. 
Under the alkaline conditional at the end of 8 h, same active 
compounds peaks was disappeared. 
Çağlar et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 10, 421-428 
 
425 
For photo degradation studies, all standards solution exposed to UV-
light for 35 h: in these condition no a large amount of fall in peaks area. 
For thermal degradation studies, all standard solutions were heated 
for 2 h and 8 h at 60 ⁰C and 80 ⁰C, respectively: in these condition no 
a large amount of fall in peaks area. 
The all results were given Table 4. 
 Analysis of samples 
Chromatograms of the some samples were shown below (Fig.6-12). 
The amount of each active compound was appointed using 
calibration curve method. The results demonstrate that the label 
claims of drugs close with obtained results which confirms the good 
accuracy of the proposed method (Table 5, Table 6). 
 
Table 3: The intra-assay (intra-day) and between-assay (inter-day) precision and accuracy results (n=5) 











Acetaminophen 50 1.4420 101.6520 1.4658 101.9980 
100 0.6876 100.3878 0.6902 101.2141 
250 1.0201 100.5995 1.1025 102.3410 
Pseudoephedrine 
HCI 
50 3.3608 98.7927 3.7541 96.3060 
100 1.3449 100.0609 1.3457 100.2120 
250 0.3759 99.9519 0.3854 100.5387 
Pheniramine 
Maleate 
50 2.3691 99.1892 2.3499 100.1165 
100 1.2286 101.1458 1.2427 103.1933 
250 1.0122 99.4358 1.0065 100.0570 
Guaifenisin 50 0.9491 100.8194 0.9569 101.0235 
100 0.7833 100.2711 0.7854 100.3749 
250 2.2236 101.6682 2.5607 103.1516 
Pyrilamine 
Maleate 
50 3.9870 101.2402 4.0364 103.0688 
100 3.3658 100.8789 3.3954 101.0122 
250 3.9282 99.0023 3.8890 100.0521 
Chlorpheniramine 
Maleate 
50 2.5739 101.8374 2.6212 102.056 
100 0.5632 100.9189 0.5684 100.9465 
250 1.4962 101.3465 1.5163 102.9471 
Tripirolidine HCI 50 2.2186 100.0368 2.9564 101.5857 
100 1.6736 102.1042 1.7089 103.2254 
250 2.0286 101.1976 2.6815 103.8761 
Dextromethorphan 
HBr 
50 2.0466 99.5917 2.9157 102.0081 
100 2.0346 101.4256 2.0636 101.9875 
250 1.2113 100.8714 1.2218 101.0159 
Diphenhydramine 
HCI 
50 1.1565 100.6600 1.1641 101.1572 
100 0.4162 100.2087 0.4170 100.8704 
250 0.4766 99.4162 0.4738 99.9141 
 
Table 4: The results of stress tests 
 Recovery(%)a 
 HCIb H2O2b NaOHb   Photolitic    
















UV Lamp35 h 2 h  
60 
⁰C     
8 h 
60 
⁰C     
 24 h 
60 ⁰C     
2 h  
80 ⁰C     
8 h 
80 
⁰C     
24 h 
80 
⁰C     
Acetaminophen 56.12 0 99.5 86.3 53.8 0 94.5 99.1 98.6 98.7 98.9 96.6 97.3 
Pseudoephedrine HCI 73.07 65.8 97.3 95.6 80.5 74.6 91.1 98.9 97.3 96.9 98.3 96.5 95.9 






93.1 84.3 70.9 57.2 72.7 96.5 95.7 89.1 94.1 88.2 85.4 
Guaifenisin 94.1 91.9 98.2 95.7 83.5 63.8 90.5 99.8 99.2 98.6 99.3 98.9 98.0 
Pyrilamine Maleate 76.7 36.3 89.9 86.2 46.8 0 74.4 96.8 95.2 89.7 89.2 85.9 82.9 
ChlorpheniramineMaleate 90.4 78.2 94.7 75.9 54.9 20.9 54.3 95.8 94.3 90.1 93.5 90.5 87.3 
Triprolidine HCI 81.1 71.7 90.4 79.4 23.3 0 82.0 95.1 93.0 89.4 92.4 88.7 85.8 
Dextromethorphan HBr 84.7 63.9 98.8 92.7 93.0 36.4 71.5 99.2 98.5 96.5 98.8 96.1 92.7 
DiphenhydramineHCI 18.9 6.6 97.5 85.9 30.3 0 72.5 99.5 97.6 88.7 98.6 90.8 87.2 
aRecovery(%) = [(mg.mL-1) after stres/(mg.mL-1) initial analyze] x 100; bStress conditions 
 
 
Fig. 6: The chromatogram belongs to corsal syrup, 1, acetaminophen; 2, sodium benzoate; 3, ISTD; 4, chlorpheniramine maleate. 
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Fig. 7: The chromatogram belongs to actidem syrup, 1, pseudoephedrine HCI; 2, sodium benzoate; 3, ISTD; 4, triprolidine HCI; 5, 
dextromethorphan HBr. 
 
Fig. 8: The chromatogram belongs to actifed syrup, 1, pseudoephedrine HCI; 2, sodium benzoate; 3, ISTD; 4, triprolidine HCI 
 
Fig. 9: The chromatogram belongs to aferin syrup, 1, acetaminophen; 2, pseudoephedrine HCI; 3, sodium benzoate; 4, ISTD; 5, 
chlorpheniramine maleate. 
 
Fig. 10: The chromatogram belongs to benical syrup, 1, pseudoephedrine HCI; 2, sodium benzoate; 3, ISTD; 4, chlorpheniramine maleate; 
5, dextromethorphan HBr. 
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Fig. 11: The chromatogram belong to peditus syrup, 1, acetaminophen; 2, guaifenisin; 3, pyrilamine maleate; 4, sodium benzoate; 5, ISTD. 
 
Fig. 12: The chromatogram belongs to kongest tablet, 1, acetaminophen; 2, ISTD; 3, chlorpheniramine maleate. 
 
Table 5: Content of commercial cough syrup with respect to label amount claimed 






















































































Sudafed Pseudoephedrine HCI 6000  6003.1±2.1 +0.05 
 
Table 6: Content of commercial cough tablet with respect to label amount claimed. 


















































Sudafed Pseudoephedrine HCI 1200  1205.6±1.78 +0.47 
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The obtained results were satisfactory for each compound. Because 
they show that the content of drug corresponds to the drug label. 
Therefore they confirm the good accuracy of the proposed method.  
CONCLUSION 
A basic and reliable HPLC method has been developed and validated 
for the determination of pseudoephdrine HCI, pheniramine maleate, 
acetaminophen, guaifenisin, pyrilamine maleate, chlorpheniramine 
maleate, triprolidine HCI, dextromethorphan HBr and 
diphenhydramine HCI in cough and cold pharmaceuticals. Compared 
to the other reported ones, the developed method offers separation 
of a large number of the active ingredients simultaneously. Thus 
large number of cough and cold pharmaceuticals could be analyzed 
by only one method. Forced degradation studies led to understand 
the chemical properties of drug molecules. Stability-indicating 
nature of the method was demonstrated on the experimental cough 
and cold syrup preparation under oxidation, acidic and alkaline, UV-
light and thermal stress conditions. Although there is no acceptance 
criteria concerning degradation products, stability study provided to 
predict usage and storage conditions of the syrup. 
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